Results 121 to 130 of about 14,670,208 (357)

Brief introduction in phenotypic and genetic differences of C57BL/6 and BALB/c mice substrains

open access: yesAnimal Models and Experimental Medicine
Experimental mice play a critical role in biomedical research. The phenotype and application of different substrains vary due to genetic differentiation and variation.
Lan Zhao, Jie Wei, Bingfei Yue
doaj   +1 more source

Determination of α-hydroxy acids in cosmetics by UHPLC-MS/MS

open access: yesShanghai yufang yixue
ObjectiveTo establish a UHPLC-MS/MS quantitative method for the determination of glucuronic acid, tartaric acid, glycolic acid, malic acid, lactic acid, citric acid, DL-2-hydroxybutyric acid sodium, mandelic acid, benzilic acid, hydroxycaprylic acid ...
RU Ge   +5 more
doaj   +1 more source

Therapeutic Drug Monitoring of Antibody Drugs

open access: yesBiological and Pharmaceutical Bulletin, 2022
In recent years, many antibody drugs that play an important role in the pharmacotherapy of several diseases have been developed. Antibody drugs exhibit immunogenicity in vivo leading to the development of antibodies against the antibody drug (anti-drug antibody). Nonetheless, other factors also affect the pharmacokinetics of antibody drugs.
openaire   +2 more sources

Autophagy and mitophagy in pancreatic β‐cell homeostasis and their involvement in diabetes pathophysiology

open access: yesFEBS Letters, EarlyView.
This review focuses on the role of autophagy and mitophagy in maintaining pancreatic β‐cell function and homeostasis. We discuss how genetic defects affecting these pathways contribute to the development of type 1, type 2, monogenic, and gestational diabetes. We further explore their potential as therapeutic targets. Created in BioRender.
Yunkyeong Lee   +2 more
wiley   +1 more source

Personalized therapy for oral anticancer drugs: an integrated approach based on therapeutic drug monitoring and pharmacogenetics for sunitinib and imatinib. [PDF]

open access: yes, 2022
openOral anticancer drugs have substantially enhanced treatment options for patients with cancer: from the use of cytotoxic drugs and non-specific chemotherapy to chronic oral treatment with targeted molecular therapies.
ZINATO, MADDALENA
core  

Predictive Performance of Bayesian Methods to Forecast Vancomycin Concentration for Therapeutic Drug Monitoring in Critically Ill Pediatric Patients

open access: yesPharmaceutics
Background: This study aimed to evaluate different Bayesian algorithms and the first-order pharmacokinetics (PK) equation approach for forecasting vancomycin concentrations in critically ill pediatric patients and to identify influencing factors. Methods:
Ha T. Pham   +11 more
doaj   +1 more source

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

open access: yesFEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante   +10 more
wiley   +1 more source

Quantitative Surveys in Hard-to-Reach Populations: The Experience of the ‘Observatoire Français Des Drogues Et Des Toxicomanies’

open access: yesMethodological Innovations, 2010
This article presents a research device (drawn up by the ‘Observatoire français des drogues et des toxicomanies' or OFDT) for exploring drug consumption practices among ‘hard-to-reach users’.
Agnès Cadet-Taïrou   +3 more
doaj   +1 more source

Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update

open access: yesTherapeutic Drug Monitoring, 2018
Background: Antiepileptic drugs (AEDs) are the mainstay of epilepsy treatment. Since 1989, 18 new AEDs have been licensed for clinical use and there are now 27 licensed AEDs in total for the treatment of patients with epilepsy.
P. Patsalos, E. P. Spencer, D. Berry
semanticscholar   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

open access: yesFEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy